Survival predictor for diffuse large B cell lymphoma

A method of treating a subject for diffuse large B cell lymphoma (DLBCL) which method comprises:

• i) evaluating the subject for antiangiogenic therapy of DLBCL, comprising:
• a) isolating gene expression product from one or more DLBCL biopsy samples from the subject;
• b) obtaining a gene expression profile from the gene expression product by detecting an expression level for VWF, CD31 (PECAM1), EGFL7, MMRN2, GPR116, and SPARCL, KDR (VEGF receptor-2), Grb10, integrin alpha 9, TEK, ROBO4, ERG, CAV1, CAV2, and EHD2;
• c) determining the subject's signature value from the gene expression profile;
• and
• d) determining whether the subject's signature value is higher or lower than a standard value, wherein antiangiogenic therapy is indicated by a signature value that is higher than the standard value and antiangiogenic therapy is not indicated by a signature value that is not higher than the standard value,
• ii) determining that the subject's signature value is higher than the standard value, and
• iii) treating the subject with antiangiogenic therapy.